OPGx-BEST1 Cohort 2 Dosing Complete and Data Expected in Q1 2027 OPGx-LCA5 Registrational Phase 3 Trial Fully Enrolled with Initiation of Dosing Expected in Q4 2026 FDA Clearance of IND for OPGx-RDH12, with Phase 1/2 Trial Dosing Planned for Q4 2026 FDA Approval of Phentolamine Ophthalmic Solution 0.75% for Presbyopia Triggers Milestone Payment Cash Runway into 2029 Expected to Support Multiple Clinical Inflection Points and Opportunities for Priority Review Vouchers RESEARCH TRIANGLE PARK, N.C.
Viatris (VTRS) and Opus Genetics (IRD) win FDA label expansion for the Ryzumvi eye care solution as a treatment for presbyopia. Read more here.
Detailed price information for Mckesson Corp (MCK-N) from The Globe and Mail including charting and trades.
2026-10-04. The following slide deck was published by Opus Genetics, Inc.
Opus Genetics, Inc. (NASDAQ:IRD) reported on September 9 that all five low-dose BIRD-1 participants showed clinically meaningful improvement on at least one visual-function measure after treatment with investigational gene therapy OPGx-BEST1. The open-label Phase 1/2 cohort included three participants with Best vitelliform macular dystrophy followed for three months and two with autosomal recessive bestrophinopathy followed […]
(Corrects ticker to IRD.) Opus Genetics (IRD) has an average rating of buy and mean price target
Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts
Opus Genetics (IRD) has an average rating of buy and mean price target of $13, according to analysts
Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study
Opus Genetics (NASDAQ:IRD) reported positive low-dose Cohort 1 data from its Phase 1/2 BIRD-1 trial of OPGx-BEST1, alongside FDA alignment on potential pivotal endpoints and a development path that could lead to Phase 3 participant dosing in 2027. Key Investor TakeawaysAll five low-dose participants showed clinically meaningful improvement in at least one measure of visual function, while four of five showed structural retinal improvements.
Opus Genetics (IRD) has an average rating of buy and mean price target of $10.71, according to analy
Topline data from Phase 1/2 Cohort 1 of OPGx-BEST1 gene therapy program to be presented during investor conference call and webcast on September 9 at 8:00 a.m. ET Full clinical dataset and additional analyses evaluating key measures of visual function to be presented at upcoming medical meetings RESEARCH TRIANGLE PARK, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”), a clinical-stage biopharmaceutical company developing gene therapies to restore vision and
Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.
This is the newest page. Registered accounts read further back.